0001209191-17-042164.txt : 20170628 0001209191-17-042164.hdr.sgml : 20170628 20170628175057 ACCESSION NUMBER: 0001209191-17-042164 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170626 FILED AS OF DATE: 20170628 DATE AS OF CHANGE: 20170628 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: INGRAM DOUGLAS S CENTRAL INDEX KEY: 0001190644 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 17936357 MAIL ADDRESS: STREET 1: 2525 DUPONT DR CITY: IRVINE STATE: CA ZIP: 92612 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-06-26 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001190644 INGRAM DOUGLAS S 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 1 1 0 0 President & CEO Common Stock 2017-06-26 4 A 0 335000 0.00 A 335000 D Stock Option (right to buy) 34.65 2017-06-26 4 A 0 3300000 0.00 A 2027-06-26 Common Stock 3300000 3300000 D Represents shares of restricted stock. Twenty-five percent of the shares will vest on June 26, 2018 and one thirty-sixth of the remaining unvested shares will vest on each monthly anniversary of June 26 thereafter, ending on June 26, 2021, in each case subject to the Reporting Person's continued service to the Issuer or a subsidiary thereof from the date of grant through each applicable vesting date. On June 26, 2022, subject to the Reporting Person's continued service to the Issuer or a subsidiary thereof from the date of grant through such date, a percentage of the stock options will vest based on the extent to which the compounded annual growth rate ("CAGR") of the Issuer's stock price from June 26, 2017 (based on the closing price on such date) through June 26, 2022 (based on the average of the closing price of the Issuer's common stock on the 20 days immediately preceding such date) exceeds the CAGR of the NASDAQ Biotech Index (or any successor index) during the same period. In certain situations, the stock options will expire within twelve months of such situation, but in no event will the stock options be exercisable after June 26, 2027. /s/ David Tyronne Howton, as Attorney-in-Fact for Douglas S. Ingram 2017-06-28